)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Cinclus Pharma (CINPHA) investor relations material
Cinclus Pharma Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary20 Aug, 2025
Executive summary
Strategic alliance and license agreement with Zentiva for linaprazan glurate commercialization in Europe, valued up to EUR 220 million, with upfront, milestone payments, and tiered royalties exceeding 20%.
Linaprazan glurate positioned as a next-generation PCAB for severe erosive GERD, with global rights and recent strategic partnerships in Asia and Europe.
Phase II data showed strong efficacy and safety, with published results demonstrating high healing rates and superiority over PPIs; Phase III trial preparations are complete, with topline data expected in 2026.
Waivers from EMA and FDA for pediatric studies in H. pylori, reducing regulatory burden and extending US data exclusivity.
Participation in major gastroenterology congresses and increased specialist engagement, highlighting clinical progress.
Financial highlights
Net sales for Q2/H1 2025 were SEK 34.1M (TSEK 34,095), mainly from Zentiva licensing revenue.
Cash at period end: SEK 589M (TSEK 588,959), up from SEK 524M in Q1 2025.
Operating expenses: SEK -42.7M in Q2, higher due to Phase III and one-time Zentiva transaction expense (SEK 18.5M).
EBIT for Q2 2025: SEK -45.9M (TSEK -45,906); Net profit: SEK -48.5M (TSEK -48,450), impacted by one-time expenses and higher R&D.
R&D expenses: SEK 4M, 85-86% of OpEx, driven by Phase III preparations and CMC activities.
Outlook and guidance
Phase III trial to recruit 500 patients at over 100 sites, with topline data expected in 2026.
European approval and launch targeted for 2029-2030 via Zentiva; approval in China expected in 2026.
US commercialization rights retained; future US deal could fully fund development.
Current working capital sufficient to fund operations through Phase III readout; further funding needed for additional programs.
US deal potential to fund development?
How to capture patients from vonoprazan?
H. pylori exclusivity benefit for Cinclus?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Cinclus Pharma earnings date
Q3 202520 Nov, 2025
Next Cinclus Pharma earnings date
Q3 202520 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Cinclus Pharma Holding AB is a clinical-stage pharmaceutical company based in Stockholm, Sweden. The company specializes in the development of treatments for acid-related diseases. Its primary focus is on a drug candidate called linaprazan glurate, which is being developed for the treatment of gastroesophageal reflux disease (GERD) and Helicobacter pylori infections. Linaprazan glurate is designed as a Potassium-Competitive Acid Blocker (P-CAB), offering a potentially more effective alternative to traditional Proton Pump Inhibitors (PPIs) used in treating acid-related conditions. Cinclus Pharma Holding AB is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq Stockholm.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage